- Moleculin Biotech (NASDAQ:MBRX) initiated with Buy rating and $8 (373% upside) price target by Roth Capital. Shares up 7% premarket on light volume.
- Audentes Therapeutics (NASDAQ:BOLD) initiated with Buy rating and $37 (18% upside) price target by H.C. Wainwright.
- Acer Therapeutics (NASDAQ:ACER) initiated with Buy rating and $50 (317% upside) price target by H.C. Wainwright.
- Voyager Therapeutics (NASDAQ:VYGR) initiated with Buy rating and $32 (129% upside) price target by BTIG Research.
- G1 Therapeutics (NASDAQ:GTHX) initiated with Buy rating and $38 (97% upside) price target by BTIG Research.
- BioCryst Pharmaceuticals (NASDAQ:BCRX) initiated with Equal Weight rating and $6 (20% upside) price target by Barclays.
- Biogen (NASDAQ:BIIB) upgraded to Outperform by Credit Suisse.
- Quorum Health (NYSE:QHC) upgraded to Equal Weight by Morgan Stanley.
- Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Neutral by Goldman Sachs.
- Varex Imaging (NASDAQ:VREX) upgraded to Neutral by JPMorgan.
- HCA Healthcare (NYSE:HCA) and Tenet Healthcare (NYSE:THC) downgraded to Underweight by Morgan Stanley citing exposure to CVS Health and UnitedHealth after recent vertical integration deals. Both down 1% premarket on light volume.
- Genomic Health (NASDAQ:GHDX) downgraded to Market Perform by William Blair.
- Gilead Sciences (NASDAQ:GILD) downgraded to Neutral by Credit Suisse. Shares down 1% premarket on modest volume.
- Aetna (NYSE:AET) downgraded to Equal Weight by Morgan Stanley.